SharkNinja shares soar 11% as third quarter results crush expectations
Investing.com -- Sandoz Group AG (SIX:SDZ) on Thursday reported third-quarter net sales of $2.83 billion, up 6% at constant currencies (CC) and 9% in reported terms, as the company upgraded its full-year profit margin guidance on the strength of its biosimilar business.
The global generic medicines leader saw volume growth of 8% in the quarter, partially offset by price erosion of 2%. Biosimilars represented more than 30% of net sales for the first time, growing 13% at constant currencies to $862 million.
The company maintained its full-year sales growth outlook of mid-single-digit percentage at constant currencies but raised its core EBITDA margin guidance to 21-22%, up from its previous target of around 21%.
"The third quarter once again demonstrated the ability of Sandoz to deliver on its commitments and execute against the strategic roadmap," said Richard Saynor, Chief Executive Officer of Sandoz. "Our comprehensive launch program is helping us expand access to affordable medicines for more patients."
By region, Europe led growth with Q3 sales of $1.53 billion, up 6% at constant currencies and 12% in reported terms. North America delivered $636 million in sales, increasing 7% at CC, while International sales reached $659 million, up 4% at CC.
The company’s generics business, which accounted for 69% of Q3 sales, grew 3% at constant currencies to $1.96 billion. Sandoz continues to execute on its launch program, with recent introductions including Wyost & Jubbonti (denosumab) and Pyzchiva (ustekinumab) in the US.
"The upgrade in our guidance for the year particularly reflects the success of our biosimilars and the excellence in execution by colleagues around the world," said Remco Steenbergen, Chief Financial Officer of Sandoz.
For the first nine months of 2025, Sandoz reported net sales of $8.06 billion, up 5% at constant currencies and in reported terms, with volume growth of 8% partially offset by price erosion of 3%.